

213<sup>th</sup> Conference Series Conference

# Scientific Program

## 4<sup>th</sup> International Conference on **Vaccines & Vaccination**

September 24-26, 2014 Valencia Convention Centre, Spain

### Sponsors & Exhibitors



### Media Partners



#### “Organize your Events at Conference Series Conferences”

Proposals are invited for organizing Symposia/Workshops at Conference Series Conferences or Conference Series will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to [contact@conferenceseries.com](mailto:contact@conferenceseries.com)

#### Conference Series Conferences

5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA

Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499

Email: [americanvaccines@conferenceseries.net](mailto:americanvaccines@conferenceseries.net); [americanvaccines@vaccineconference.com](mailto:americanvaccines@vaccineconference.com)

# Opening Ceremony

## Keynote Forum

### Introduction

#### Ray Spier

University of Surrey, UK

#### Michael G Hanna

Vaccinogen, Inc., USA

#### Nikolai Petrovsky

Flinders Medical Centre Research, Australia

Group Photo

Coffee Break

### Vaccine adjuvants

**Session Chair:** Nikolai Petrovsky, Flinders Medical Centre Research, Australia

**Title:** Inter-bilayer cross-linked multi-lamellar vesicles (ICMV) for efficient co-delivery of antigen and adjuvant payloads

Alan R Shaw, Vedantra Pharmaceuticals, USA

**Title:** Adjuvant-guidance of T cell responses

Magdalena Tary-Lehmann, Cellular Technology Limited, USA

**Title:** Antibody targeting of human T cell CD27 identifies genes and pathways related to inflammation

Venky Ramakrishna, Celldex Therapeutics, USA

**Title:** Evaluation of ZOSTAVAX® via the intradermal route using the MicronJet™

Brian K. Meyer, Merck & Co., USA

**Title:** Universal influenza vaccines: Prevention of infection against matched and mismatched strains

Harry Kleanthous, Sanofi-Pasteur, Inc., USA

**Title:** DNA vaccines which encode natural adjuvants are more effective than canonical DNA vaccines

Eric James Gowans, The University of Adelaide, South Australia

Lunch Break

**Title:** Immune memory resilience, a new way of evaluating adjuvants

Jean-Pierre Y Scheerlinck, The University of Melbourne, Australia

**Title:** Novel lipid based adjuvants and delivery systems for induction of CD8 T cell immunity

Lakshmi Krishnan, National Research Council-Human Health Therapeutics, Canada

**Title:** Establishment of lipid-based immunogens for the development of novel subunit vaccines

Chih-Hsiang Leng, National Health Research Institutes, Taiwan

**Title:** Highly immunogenic C-terminal binding domain of *Clostridium difficile* toxin a stimulates dendritic cell maturation

Pele Choi-Sing Chong, National Health Research Institutes, Taiwan

Coffee Break

**Title:** The Cronobacter sakazakii ESP2949-1 phage induces dendritic cell maturation via activation of nuclear factor-κB and IL-12p40 in murine bone marrow

Hyo-lhl Chang, Korea University, Korea

**Title:** Nasal administration of antigens using maltodextrin nanoparticles: A mechanistic study

Didier Betbeder, University of Lulle2, France

**Title:** Stabilized liposomes carrying bee venom new formulation is the breakthrough of pain and anaphylaxis and death in mice under venom immunotherapy

Maria Helena Bueno da Costa, Scientific Consultant, France

**Title:** Live vaccine for equine influenza on the base of cold-adapted recombinant strain A/HKOTar/6:2/2010

Sandybayev Nurlan, Research Institute for Biological Safety Problems, Republic of Kazakhstan

**Title:** Polio outbreak in the Middle East: Update

Randa Hamadeh, Ministry of Public Health, Lebanon

**Title:** Outer membrane vesicle of bacteria: Friend or Foe?

Seyed Davar Siadat, Pasteur Institute of Iran, Iran

**Title:** Adjuvant properties of outer-membrane-vesicle in hepatitis B surface based vaccine

Arfa Moshiri, Shahid Beheshti University of Medical Sciences, Iran

**Title:** Role of interferon gamma as immune adjuvant in *Labeor ohita*

Megha Kadam Bedekar, Central Institute of Fisheries Education, India

Panel Discussion

**Biodefense vaccine**

**Session Chair:** Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA

**Title:** Finding a safe, efficacious and stable vaccine in the ricin protein fold

**Leonard A Smith**, United States Army Medical Research Institute of Infectious Diseases, USA

**Title:** A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation

**Connie S Schmaljohn**, United States Army Medical Research Institute of Infectious Diseases, USA

**Title:** MVA-BN<sup>®</sup> (IMVANEX<sup>®</sup>/IMVAMUNE<sup>®</sup>): A non-replicating, new generation smallpox vaccine available for updating smallpox preparedness plans

**Nathaly Arndtz-Wiedemann**, Bavarian Nordic GmbH, Germany

**Title:** A vaccine pipeline: Using phage display for identification of immunogenic proteins and generation of human antibodies for diagnostics and therapy

**Michael Hust**, Technische Universität Braunschweig, Germany

Panel Discussion

Lunch Break @ Multi Purpose Hall 2

**Veterinary vaccines**

**Session Chair:** Jean L Patterson, Texas Biomedical Research Institute, USA

**Title:** Quality and consistency of cell culture media with a highlight on FMDV

**Serge Ohreser**, Merck Millipore, France

**Title:** Vaccine development at animal biosafety level four: Standards and challenges

**Jean L Patterson**, Texas Biomedical Research Institute, USA

**Title:** Low dose antigen exposure in extreme early life promotes adaptive immune response in lambs and piglets

**Heather L Wilson**, University of Saskatchewan, Canada

**Title:** Study immune correlates of vaccine-induced protective immunity against rotavirus infection and diarrhea using B cell deficient neonatal gnotobiotic pigs

**Lijuan Yuan**, Virginia Polytechnic Institute and State University, USA

**Title:** Targeting aminopeptidase N on enterocytes rapidly induces an IgA response in a pig model

**Eric Cox**, Ghent University, Belgium

**Title:** Use of ORF-1 product Rep in prevention and diagnosis of porcine circovirus

**Silvia Pellicer**, World Pathol, Spain

Coffee Break @ Auditorium 3 Foyer

**Title:** Properties of ghost bacterial cells obtained by hybrid material with silver nanoparticles (PVA/ AgNps) as well as their opportunities for use in vaccine prophylactics

**Daniela Pencheva**, Bul Bio - NCIPD Ltd., Bulgaria

**Title:** Impact of three inactivated bovine viral diarrhoea (BVD) vaccines on bulk milk p80 (NS3) ELISA readings in commercial Irish dairy herds

**Riona Sayers**, Animal & Grassland Research and Innovation Center, Ireland

**Title:** Construction of Phix174 gene E mediated lysis system for generation of *Salmonella Enteritidis* ghost, and its evaluation as a vaccine candidate for the immunogenicity and protective efficacy against avian salmonellosis

**Chetan V Jawale**, Chonbuk National University, Republic of Korea

**Title:** Use of viral interference against avian influenza and establishment of protection levels in field outbreaks in Mexico

**Inkar Castellanos**, Viren SA de CV, Mexico

Panel Discussion

Day 2 September 25, 2014

Auditorium 3A

**Keynote Forum**

**Introduction**

**Geert Vanden Bossche**

UNIVAC LLC., Belgium

**Jeffrey Ulmer**

Novartis Vaccines & Diagnostics, USA

Group Photo

**Therapeutic vaccines for chronic infecti**

**Session Chair:** Jeffrey Ulmer, Novartis Vaccines & Diagnostics, USA

**Title:** Mimogen-a new strategy for post-exposure vaccine development

**Yuzhang Wu**, Third Military Medical University, China

**Title:** Generation of robust immunity following DNA vaccine immunization enhanced by intradermal electroporation

**Kate E Broderick**, Inovio Pharmaceuticals, USA

**Title:** M2SR, a robust flu vaccine with long-lasting, cross-protective immunity

**Pamuk Bilsel**, Flugon Inc., USA

Coffee Break @ Auditorium 3 Foyer

**Title:** In vivo electroporation for improvement of therapeutic DNA vaccine against chronic hepatitis B infection

**Lucyna Cova**, INSERM, France

**Title: A Synthetic multi-antigen approach targeting *Plasmodium falciparum* malaria**

**Bernadette Ferraro**, University of Pennsylvania, USA

**Title: Pneumococcal infections and vaccination**

**Birgitta Henriques-Normark**, Karolinska Institute, Sweden

**Title: Heat shock protein complex vaccines against mucosal pathogenic bacteria**

**Phil Sutton**, Murdoch Childrens Research Institute, Australia

**Title: Upgrading the 100 year-old BCG vaccine**

**Zakaria Hmama**, University of British Columbia, Canada

**Lunch Break @ Multi Purpose Hall 2**

**Title: Immunization with neuraminidase deficient influenza virus is highly immunogenic and non-pathogenic to wild type and immunocompromised mice**

**Alexandre M. Vieira Machado - Fiocruz**, Rene Rachou Research Center, Brazil

**Title: Design and evaluation of a novel OspA-based vaccine for the prevention of Lyme borreliosis**

**Andreas Meinke**, Valneva Austria GmbH, Austria

**Title: Therapeutic vaccines for drug-resistant tuberculosis**

**Tjip van der Werf**, University of Groningen, The Netherlands

**Title: Vaccination in risk groups with special focus on non-responsiveness to routine vaccines**

**Ursula Wiedermann**, Medical University of Vienna, Austria

**Title: Post challenging effects of new formulation of leishmania major antigen in Balb/c mice**

**Latifynia Afshineh**, Tehran University of Medical Sciences, Iran

**Coffee Break @ Auditorium 3 Foyer**

**Title: Immunological studies on tetanus toxoid**

**Rakesh Kumar**, Serum Institute of India Limited, India

**Title: Process development and immunogenicity studies on a serogroup 'X' meningococcal polysaccharide conjugate vaccine**

**Srinivas Reddy**, Serum Institute of India Ltd., India

**Title: Self-adjuvanting promiscuous peptide of Mycobacterium tuberculosis augments polyfunctional Th17 cells and evokes better memory T cell response than BCG**

**Javed N Agrewala**, CSIR - Institute of Microbial Technology, India

**Title: Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis**

**Xueqiong Wu**, the 309<sup>th</sup> Hospital of Chinese PLA, China

**Title: Speciation of chromium in medicinal plants from selected farms in the vicinity of ferrochrome**

**Isiaka Alade Owolabi**, Tshwane University of Technology, South Africa

**Panel Discussion**

**Special Session for Students: Nikolai Petrovsky @ Community Hall 1-2**

**Scientific writing, Journal review, Grant writing, Strategies for building a scientific career and Scientific careers outside of research**

**Breakout @ Committee Room 6-7**

**Cancer vaccines**

**Session Chair: Michael G Hanna**, Vaccinogen, Inc., USA

**Title: From viruses to tumor associated antigen cancer vaccines**

**Giulio Tarro**, Temple University Center for Biotechnology, USA

**Title: Measles Virus vaccine infects tumor cells and induces dendritic cells (DC) maturation and tumor antigen cross-presentation**

**Marc GREGOIRE**, Institut de Recherche en Sante Universite de Nantes, INSERM, France

**Title: Personalized therapeutic cancer vaccine development to treat metastatic diseases**

**Periasamy Selvaraj**, Emory University, USA

**Coffee Break @ Auditorium 3 Foyer**

**Title: Teaching self-destructing Salmonella new tricks to fight cancer**

**Wei Kong**, Arizona State University, USA

**Title: DC targeting skin vaccines for improved cancer immunotherapy**

**Yvette van Kooyk**, VU University Medical Center, The Netherlands

**Title: Acceptability of human papillomavirus vaccine: A survey among master of business administration students in KwaZulu-Natal, South Africa**

**M E Hoque**, University of KwaZulu-Natal, South Africa

**Panel Discussion**

**AIDS/HIV vaccine**

**Title: Antigenicity, structure and immunogenicity of the HIV-1 trimeric envelope glycoprotein spike**

**Richard T Wyatt**, The Scripps Research Institute La Jolla, USA

**Lunch Break @ Multi Purpose Hall 2**

**Title: Application of neutralization fingerprints in delineating antibody recognition in HIV-1 sera and antibody epitope prediction**

**Gwo-Yu Chuang**, National Institutes of Health, USA

**Title: The balance of cellular and humoral immunity determines the level of protection offered by an HIV vaccine in macaque models of HIV infection**

**Timothy Fouts**, Profectus BioSciences, Inc., USA

**Title: VAC-3S vaccine, a novel approach to the therapeutic management of HIV infection. Overview of phase I and phase II clinical vaccine development programs**

**Raphael Ho Tsong Fang**, InnaVirVax, France

**Title: Characterization of a potent and broad neutralizing antibody that specifically recognizes a point-substitution in the 3S motif of the HIV-1 gp41 protein**

**Patrice DEBRE**, INSERM, France

**Title: Glycosylation of envelope gp120 is affected by producer cell type and impacts HIV-1 recognition by virus-specific antibodies and cell infection**

Milan Raska, Palacky University, Czech Republic

Coffee Break @ Auditorium 3 Foyer

**Title: DNA vaccination against drug resistance in chronic viral infections, example of HIV-1**

Maria ISAGULIANTS, Karolinska Institutet, Sweden; Riga Stradins University, Latvia

**Title: Evaluation of immune response in small animal models by in vivo imaging**

Stefan Petkov, Karolinska Institutet, Sweden

**Title: Human clinical trial of SAV001 prophylactic HIV vaccine and a new strategy for the development of therapeutic HIV vaccine**

Chil-Yong Kang, The University of Western Ontario, Canada

#### Panel Discussion

#### Vaccine antigen modeling

**Title: Optimizing the delivery of novel immune potentiators within vaccine drug products**

Manmohan Singh, Novartis Vaccines, USA

**Title: Natural killer cell subsets display helper and suppressor effects in modulating host viral responses in vivo**

William J Murphy, UC Davis School of Medicine, USA

**Title: Strategies of antigen retargeting for improvement of DNA vaccine performance**

Elizaveta Starodubova, Karolinska Institutet, Sweden

**Title: Cellular vaccines in Listeriosis: Role of the *listeria* antigen GAPDH**

Carmen Alvarez-Dominguez, Instituto de Formacion e Investigacion Marques de Valdecilla, Spain

**Title: Regulation of STING expression via the RIG-I dependent RNA sensing pathway**

Rongtuan Lin, McGill University, Canada

**Title: Cell engineering and antibiotic-free selection for vaccinal antigens production in *E. coli*: The ultimate sophistication to combine safety and productivity**

Regis Sodoyer, Sanofi Pasteur, France

**Title: Leishmania recombinant antigen modulates the macrophage effector functions synergizing anti-leishmanial effects of miltefosine to facilitate early clearance of intracellular parasites**

Sunil K Arora, PGIMER, India

Day 3

September 26, 2014

Auditorium 3A

#### Immuno-informatics in vaccine design

Session Chair: Malcolm E Thomas, Arbovax., Inc., USA

**Title: Immunization and human rights**

Obradovic Zarema, University of Sarajevo, Bosnia and Herzegovina

**Title: SIgN's clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials**

Brian Abel, Singapore Immunology Network, Singapore

**Title: Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children**

Katie Ewer, University of Oxford, UK

**Title: The common computer-based influenza vaccination/epidemics surveillance system: Challenges and opportunities for primary health care in EU countries**

Ljiljana Majnaric Trtrica, JJ Strossmayer University, Croatia

**Title: The development of tuberculosis subunit vaccine EAMMH and regulation of vaccine induced immune memory by Rapamycin**

Bingdong Zhu, Lanzhou University, China

**Title: Immunization programme in Indonesia: Overview- (Focusing on *Streptococcus Pneumonia* whole-cell vaccine)**

Julitasari Sundoro, Indonesian Technical Advisory Group on Immunization, Indonesia

#### Panel Discussion

Coffee Break @ Auditorium 3 Foyer

#### Vaccine formulation issues

**Title: Unique nanofabrication of antigens and adjuvants that effectively induces protective antibody and T cell responses**

Frank J Malinoski, Liquidia Technologies Inc., USA

**Title: Development of a carbohydrate-based vaccine against meningococcal serogroup X infection**

Francesco Berti, Novartis Vaccines, Italy

**Title: Effect of the inclusion of "contemporary" *B. pertussis* strains in the vaccine composition on temporal trends in *B. pertussis* population**

Tatjana Pljesa, Institute of Virology, Vaccines and Sera Torlak, Serbia

**Title: Specificities of health economics in the area of vaccines evaluation**

Maarten J Postma, University of Groningen, The Netherlands

**Title: The effect of new leishmania vaccine against Th1, Th2 as well as increasing of spleen white pulp size in Bulb/c mice after repeated exposure**

Latifnia Afshineh, Tehran University of Medical Sciences, Iran

#### Panel Discussion

Lunch Break

#### Unconventional vaccines

**Title: A novel approach to the development of arboviral vaccines for dengue and chikungunya virus**

Malcolm E Thomas, Arbovax., Inc., USA

**Title: Strategies toward developing a universal ExPEC vaccine capable of broad protection**

Melha Mellata, Arizona State University, USA



**Title: The vaxonella platform for oral recombinant vaccine delivery**

Rocky M Cranenburgh, Prokarium Ltd., UK

**Title: Oral vaccine platform elicits neutralizing antibody responses to influenza**

Sean Tucker, Vaxart, Inc., USA

**Title: A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of influenza B globular head vaccines**

Langzhou Song, VaxInnate Corporation, USA

Coffee Break @ Auditorium 3 Foyer

**Title: Responsibility: A “first person ethics” for vaccination**

Fermin J Gonzalez-Melado, Pontifical Institute “John Paul II” for Studies on Marriage and Family, Spain

**Title: Development of a truly improved whooping cough vaccine**

Marcel Thalen, Iliad Biotechnologies, Scotland

**Title: Translational development and preclinical efficacy of a multiantigen T cell epitope-enriched DNA vaccine against *Leishmaniasis***

Christiane Juhls, MOLOGEN AG, Germany

**Title: Oral infections in Guinea Conakry**

Sylvain Haba, Centre Des Soins Medico-Tradi-Spirituels Talithakoumi, Guinea Conakry

Panel Discussion

Poster Presentations @ Auditorium 3 Foyer  
Day-2

**VAC-001 Title: Using NYVAC vectors as vaccine candidates for *Leishmaniasis***

Ernesto Mejias Perez, Centro Nacional de Biotecnologia, Spain

**VAC-002 Title: Enhancement of antigen-specific CD4 T cell response through spacer modification in vaccinia virus promoters**

Mauro Di Pilato, Centro Nacional de Biotecnologia, Spain

**VAC-003 Title: IL-34 suppresses *Candida albicans* induced TNF- $\alpha$  production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression**

Rong Xu, Cardiff University, UK

**VAC-004 Title: Protection of chickens against *Chlamydia psittaci* challenge by mucosal immunization with the major outer membrane protein**

Daisy Vanrompay, Ghent University, Belgium

**VAC-005 Title: The single intradermal cervical comparative test and John's disease ELISA diagnostics**

Aideen Kennedy, Animal & Grassland Research and Innovation Centre, Ireland

**VAC-006 Title: Antigen on nanoparticles enhances anti-tumor immune responses as well as humoral antibody responses *in vivo***

Junichiro Mizuguchi, Tokyo Medical University, Japan

**VAC-007 Title: Hepatitis B immunization status of a miscellaneous population of workers**

Frederic DESCHAMPS, University Hospital of Reims, France

**VAC-008 Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice**

Silvia Vendetti, Istituto Superiore di Sanita, Italy

**VAC-009 Title: Experimental chagas disease: Vaccination with *Trypanosoma rangeli* modulate the innate immune response in mice challenged with *Trypanosoma cruzi***

Beatriz Basso, National University of Cordoba, Argentina

**VAC-010 Title: Effect of preventive and therapeutic vaccination schedules with *Trypanosoma rangeli* against *Trypanosoma cruzi* infection in a mouse model of Chagas' disease**

Beatriz Basso, National University of Cordoba, Argentina

**VAC-011 Title: Generation of genetically inactivated *Salmonella Gallinarum* ghost and evaluation of its potential as an effective inactivated vaccine candidate against fowl typhoid**

Chetan V Jawale, Chonbuk National University, Korea

- VAC-012 **Title: Construction of tightly regulated E-lysis cassette for production of genetically inactivated *Salmonella* Enteritidis**  
Chetan V. Jawale, Chonbuk National University, Korea
- VAC-013 **Title: Increasing of alive plague vaccine efficiency**  
Ponomaryova Tatyana, Kazakh Scientific Center of Quarantine and Zoonotic Diseases, Kazakhstan
- VAC-014 **Title: Double-blind randomized placebo-controlled trial to evaluate cell-mediated immunity and safety of the herpes zoster vaccine in elderly patients with diabetes**  
Atsuko Hata, The Tazuke Kofukai Medical Research Institute, Japan
- VAC-015 **Title: Analysis of phage displayed antibody fragment - pros and cons of Phage ELISA and RISE methods**  
Barbara Kalenik, Institute of Biochemistry and Biophysics Polish Academy of Sciences, Poland
- VAC-016 **Title: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa**  
Athina KILPELAINEN, Karolinska Institutet, Sweden
- VAC-017 **Title: Retargeting of HIV reverse transcriptase to MHC class II processing improves its immunogenicity**  
Anastasia Latanova, Karolinska Institutet, Sweden
- VAC-018 **Title: Lipopolysaccharide of *Coxiella burnetii*. A promising candidate molecule in a search for a new Q fever vaccine**  
Rudolf Toman, Slovak Academy of Sciences, Slovak Republic
- VAC-019 **Title: Long-term immune response to Hepatitis B Virus (HBV) vaccine among type 1 diabetic students: Do they need a booster?**  
Engy M. El-Ghitany, Alexandria University, Egypt
- VAC-020 **Title: Bivalent candidate vaccine against HCV and HIV-1: Construction and biological evaluation**  
Mohammad Reza Aghasadeghi, Pasteur Institute of Iran, Iran
- VAC-021 **Title: An early report on a local project about primary health care to improve the communication and the compliance in the elderly for vaccinal campaigns against influenza**  
Filippo de Nicolellis, Primary Health Care, Italy
- VAC-022 **Title: Cyclic GMP-AMP has mucosal adjuvant activity in mice**  
Christina Rueckert, Helmholtz Center for Infection Research, Germany
- VAC-023 **Title: Local and systemic antibody and cell-mediated immune response after vaccination and infection with porcine respiratory and reproduction system (PRRS) virus**  
Miroslav Toman, Veterinary Research Institute, Czech Republic
- VAC-024 **Title: Using monoclonal antibodies to understand the molecular basis for the cross bactericidal activity of NHBA antigen**  
Claudia Facciotti, Novartis, Italy
- VAC-025 **Title: Expression profile of cytokine transcripts and Cell mediated immune response in peripheral blood mononuclear cells of sheep following vaccination of pentavalent bluetongue vaccine**  
Molalegne Bitew, Jimma University, Ethiopia
- VAC-026 **Title: In vitro molecular analysis of ribosomal initiation complexes assembly and RNA-protein interactions during the initiation of translation of a prototype Coxsackievirus B3 and a live-attenuated Sabin 3-like RNAs**  
Amira SOUII, Universite de Tunis El Manar, Tunisia

**Bookmark your dates**

20<sup>th</sup> Global Summit & Expo on

# Vaccines, Immunization & B2B

September 18-19, 2017 Houston, USA

**E-mail:** [americanvaccines@vaccineconference.com](mailto:americanvaccines@vaccineconference.com); [vaccines@annualcongress.com](mailto:vaccines@annualcongress.com)  
[americanvaccines@conferenceseries.net](mailto:americanvaccines@conferenceseries.net); [vaccines@conferencesmail.org](mailto:vaccines@conferencesmail.org)

**Website:** <http://vaccines.global-summit.com/america/>

**Conference Series LLC**  
2360 Corporate Circle, Suite 400  
Henderson, NV 89074-7722, USA  
Ph: +1-888-843-8169  
Fax: +1-650-618-1417  
[america@conferenceseries.com](mailto:america@conferenceseries.com)

**Conference Series Ltd.**  
Traian Str., No.61, Constanta 900720,  
Romania, Tel: 0805-080048  
Heathrow Stockley Park Lakeside  
House, 1 Furzeground Way, Heathrow,  
UB11 1BD, United Kingdom  
[europe@conferenceseries.com](mailto:europe@conferenceseries.com)

**Conference Series LLC**  
6th Floor, North Block, Divyasree  
Building, Raidurg Hyderabad,  
Telangana, INDIA-500032  
Tel: +91-40-33432300  
[asia.pacific@conferenceseries.com](mailto:asia.pacific@conferenceseries.com)

**Toll free**  
USA & Canada: +1-800-216-6499  
Australia: +1-800-651-097  
Europe: 0805-080048